Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
HELIUM, USP is an inhaled gas product approved by the FDA in 2013 for medical use. The product is a respiratory therapeutic gas administered via inhalation route. Specific clinical indications and mechanism of action are not publicly detailed in available regulatory summaries.
Product is in peak lifecycle stage with moderate competitive pressure (30), suggesting stable market positioning and a small, focused brand team.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
C2 Esophageal Squamous Epithelium Dysplasia
Worked on HELIUM, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Advanced Solutions Life Sciences is hiring 1 role related to this product
Only 2 linked job opportunities exist for HELIUM, USP, primarily in early-career and IT roles, reflecting the product's small organizational footprint. This represents a niche career opportunity suitable for entry-level professionals or those with specialized IT/technical skills rather than seasoned commercial pharmaceutical professionals.
2 open roles linked to this drug